NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with...
DOYLESTOWN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical...
Enrollment in the SAFEGUARD trial is ongoing at multiple centers globallyCompany on-track to share Phase 2b data in 2H 2027...
Enrollment in the SAFEGUARD trial is ongoing at multiple centers globallyCompany on-track to share Phase 2b data in 2H 2027...
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of...
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of...
Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to...
Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to...
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s...
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s...
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all...
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all...
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or...
Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years. Results suggest...
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Scientists developed an antibody treatment that...
Study examines the safety and early efficacy of an oncolytic virus via a single intravenous doseSAN DIEGO, Dec. 11, 2025...
Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden...
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease Results show, for...
In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements...
GRAND BLANC, Mich., Dec. 10, 2025 /PRNewswire/ -- ModuleMD, ranked as one of America's fastest-growing companies on the Inc. 5000...